Abstract
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease. Innate and adaptive immunity cooperatively contribute to the development of SLE. Antigen-presenting cells (APCs) have been suggested to link innate and adaptive immunity. T-cell immunoglobulin- and mucin-domain-containing molecule-4 (Tim-4; also known as Timd4), expressed primarily on the surface of APCs, is a member of the TIM family, a recently described group of molecules that have received much attention as potential regulators of the immune system. In this study, we used quantitative real-time reverse transcription-polymerase chain reaction to examine the mRNA expression of Tim-4 in peripheral blood mononuclear cells (PBMCs) from SLE patients and further analyzed the correlation between the expression of Tim-4 and Tim-1 (a potential ligand for Tim-4) in PBMCs and serum tumor necrosis factor (TNF)-α levels. The results showed that Tim-4 mRNA expression in PBMCs was significantly higher in SLE patients than in healthy controls, especially those patients in the active phase of disease. Moreover, Tim-4 mRNA levels were closely correlated with Tim-1 mRNA levels in PBMCs and with serum TNF-α levels in SLE patients but not in the control group. Taken together, these results demonstrate that Tim-4 may be involved in the pathogenesis of SLE.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mok CC, Lau CS . Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490.
Zuñiga R, Ng S, Peterson MG, Reveille JD, Baethge BA, Alarcón GS et al. Low-binding alleles of Fcgama receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients. Arthritis Rheum 2001; 44: 361–367.
Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1234–1237.
Xiang YJ, Dai SM . Prevalence of rheumatic diseases and disability in China. Rheumatol Int 2009; 29: 481–490.
Agarwal S, Elliott JR, Manzi S . Atherosclerosis risk factors in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 241–247.
Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C . Lupus and cancer. Lupus 2009; 18: 479–485.
Panopalis P, Yazdany J . Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 2009; 11: 177–184.
Bachen EA, Chesney MA, Criswell LA . Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 822–829.
Appenzeller S, Pallone AT, Natalin RA, Costallat LT . Prevalence of thyroid dysfunction in systemic lupus erythematosus. J Clin Rheumatol 2009; 15: 117–119.
Eisenberg R . Mechanisms of autoimmunity. Immunol Res 2003; 27: 203–218.
Milich DR, Gershwin ME . The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 1980; 10: 111–147.
Rönnblom L, Pascual V . The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17: 394–399.
Pisetsky DS . The role of innate immunity in the induction of autoimmunity. Autoimmun Rev 2008; 8: 69–72.
de la Fuente H, Richaud-Patin Y, Jakez-Ocampo J, González-Amaro R, Llorente L . Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE);. Immunol Lett 2001; 77: 175–180.
Zhao XF, Pan HF, Yuan H, Zhang WH, Li XP, Wang GH et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81–85.
Meijer C, Huysen V, Smeenk RT, Swaak AJ . Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2: 359–365.
Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001; 21: 3053–3059.
Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539–545.
Lourenço EV, La Cava A . Cytokines in systemic lupus erythematosus. Curr Mol Med 2009; 9: 242–254.
Katsiari CG, Liossis SN, Sfikakis PP . The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 2009; 14: in press.
Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, de Marchis F et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007–3018.
Meyers JH, Chakravarti S, Schlesinger D, Illes Z, Waldner H, Umetsu SE et al. Tim-4 is the ligand for Tim-1 and Tim-1-Tim-4 interaction regulates T cells proliferation. Nat Immunol 2005; 6: 455–464.
Rodriguez-Manzanet R, Meyers JH, Balasubramanian S, Slavik J, Kassam N, Dardalhon V et al. TIM-4 expressed on APCs induces T cell expansion and survival. J Immunol 2008; 180: 4706–4713.
Umetsu DT, Umetsu SE, Freeman GJ, DeKruyff RH . TIM gene family and their role in atopic diseases. Curr Top Microbiol Immunol 2008; 321: 201–215.
Shi HN, Walker WA . The role of TIM-4 in food allergy. Gastroenterology 2007; 133: 1723–1726.
Cai PC, Hu LH, Cui TP, Li YR, Chen FH, Wu QW . Association of TIM4 promoter polymorphism -1419G>A with childhood asthma in a Chinese Han population. Tissue Antigens 2009; 74: 11–16.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 6: 630–640.
McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001; 2: 1109–1116.
Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ . The Tim gene family: emerging roles in immunity and disease. Nat Rev Immunol 2003; 3: 454–462.
Silberstein E, Xing L, van de Beek W, Lu J, Cheng H, Kaplan GG . Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin- and mucin-like regions. J Virol 2003; 77: 8765–8774.
Umetsu SE, Lee WL, McIntire JJ, Downey L, Sanjanwala B, Akbari O et al. Tim-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol 2005; 6: 447–454.
Meyers JH, Sabatos CA, Chakravarti S, Kuchroo VK . The Tim gene family regulates autoimmune and allergic diseases. Trends Mol Med 2005; 11: 362–369.
Sabatos CA, Chakravarti S, Cha E, Schubart A, Sanchez-Fueyo A, Zheng XX et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003; 4: 1102–1110.
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245–1252.
Pan HF, Zhang N, Li WX, Tao JH, Ye DQ . TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep 2010; 37: 395–398.
Kávai M, Zsindely A, Sonkoly I, Bányai A, Szegedi G . Monocyte activation by immune complexes of patients with SLE. Adv Exp Med Biol 1982; 141: 575–582.
Jang EJ, Nahm DH, Jang YJ . Mouse monoclonal autoantibodies penetrate mouse macrophage cells and stimulate NF-kappaB activation and TNF-alpha release. Immunol Lett 2009; 124: 70–76.
Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L et al. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol 2008; 67: 63–70.
Mizui M, Shikina T, Arase H, Suzuki K, Yasui T, Rennert PD et al. Bimodal regulation of T cell-mediated immune responses by TIM-4. Int Immunol 2008; 20: 695–708.
Feng BS, Chen X, He SH, Zheng PY, Foster J, Xing Z et al. Disruption of T-cell immunoglobulin and mucin domain molecule (TIM)-1/TIM4 interaction as a therapeutic strategy in a dendritic cell-induced peanut allergy model. J Allergy Clin Immunol 2008; 122: 55–61.
Mageed RA, Isenberg DA . Tumor necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus 2002; 11: 850–855.
Aringer M, Smolen JS . Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 2003; 5: 172–177.
Richaud PY, Alcocer VJ, Liorente L . High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995; 47: 267–272.
Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S . Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 15: 435–439.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 30872298) and Independent Innovation Foundation of Shandong University (No. 2009TS115).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhao, P., Xu, L., Wang, P. et al. Increased expression of human T-cell immunoglobulin- and mucin-domain-containing molecule-4 in peripheral blood mononuclear cells from patients with system lupus erythematosus. Cell Mol Immunol 7, 152–156 (2010). https://doi.org/10.1038/cmi.2009.118
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2009.118
Keywords
This article is cited by
-
Tim-4 protects mice against lipopolysaccharide-induced endotoxic shock by suppressing the NF-κB signaling pathway
Laboratory Investigation (2016)
-
TIM-4 promotes the growth of non-small-cell lung cancer in a RGD motif-dependent manner
British Journal of Cancer (2015)